To help treat the effects of Covid-19, President Donald Trump has reportedly received dexamethasone. Deck-of-who-the-phone? Dexys Midnight Runners hold the phone? No, dexamethasone. It is a ...

Treatment with the antiviral remdesivir (Veklury) plus dexamethasone was linked to fewer deaths among patients hospitalized for COVID-19 compared with dexamethasone monotherapy, a retrospective study ...

The race for an effective treatment for Covid-19 has been littered with false starts and uncertain outcomes. To date, no treatment improves the odds of Covid-19 patients surviving. However, one ...

The president’s physician says President Trump was treated with a steroid after a drop in oxygen levels on Saturday. Dr. Sean Conley said at a news conference on Sunday that he was given the steroid ...

Dexamethasone treatment failed to demonstrate noninferiority to surgery for chronic subdural hematoma and was associated with more complications and a greater risk of later surgery, according to ...

The steroid dexamethasone has been found to reduce the risk of death in seriously ill coronavirus patients by about a third, according to clinical trial results hailed on Tuesday as a "major ...

Among patients with glioblastoma (GBM) receiving an immune checkpoint inhibitor, those who received dexamethasone at baseline for cerebral edema had significantly worse overall survival, according to ...

A paper published Friday in the New England Journal of Medicine suggests a low-cost steroid may be a valuable treatment for severe COVID-19, building upon encouraging preliminary findings from last ...

Dexamethasone has a longer half-life than prednisone or prednisolone and tastes better in liquid form; therefore, substitution of dexamethasone for prednisone/prednisolone may result in better patient ...

CARDIFF, UNITED KINGDOM - JUNE 16: A close-up of a box of Dexamethasone tablets in a pharmacy on June 16, 2020 in Cardiff, United Kingdom. Results of a trial announced today have shown that ...

Santen EMEA and NTC are delighted to announce that the results of their phase III clinical study, LEADER7, have been published in Eye. The study demonstrated for the ...